“The publication of Cryocure-2 data is seen as a significant step in the validation of Adagio’s ULTC technology,” said Olav Bergheim, President and CEO of Adagio Medical.

Artivion advises the trial is designed to support the company’s forthcoming application to the U.S. Food and Drug Administration for premarket approval of the AMDS.

Embrace Hydrogel Embolic System is an investigational device intended to be used to embolize peripheral arterial bleeds in vessels ≤ 6 mm

Renovia advises 1 study showed significantly higher costs for payers in the two years following diagnosis for women whose treatment claims did not align with published guidelines for female UI.

Samsara Vision notes the CONCERTO trial will recruit 100 adults aged 65 and older living with stable (non-active neovascularization), bilateral central scotomas (blind spots) due to late-stage AMD and fovea-involving geographic atrophy or disciform scar to receive a SING IMT™ in one eye.

Recruitment begins for a new robot study jointly run by the University of Warwick, University Hospitals Coventry and Warwickshire (UHCW) NHS Trust, and the Royal Orthopaedic Hospital in Birmingham.